Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

5.130 -0.400 (-7.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,242,537
Open 5.490
Bid (Size) 5.050 (100)
Ask (Size) 5.410 (600)
Prev. Close 5.530
Today's Range 5.060 - 5.510
52wk Range 5.060 - 14.69
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Functional Wellness Stocks Explode as $179 Billion Beverage Market Ditches Sugar for Science
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. 
From Equity Insider
Via GlobeNewswire
News headline image
Niagen Bioscience Expands HSA/FSA Access for Tru Niagen®, the Leading NAD+ Supplement in the U.S.*
From Niagen Bioscience, Inc
Via Business Wire

Performance

YTD
-17.9%
-17.9%
1 Month
-24.1%
-24.1%
3 Month
-22.3%
-22.3%
6 Month
-46.6%
-46.6%
1 Year
-33.7%
-33.7%

More News

Read More
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
From USA News Group
Via GlobeNewswire
News headline image
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces $10 Million Share Repurchase Program
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide
From Niagen Bioscience, Inc
Via Business Wire
News headline image
AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Breaking Down Niagen Bioscience: 4 Analysts Share Their Views ↗
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Niagen NAGE Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Examining the Future: Niagen Bioscience's Earnings Outlook ↗
Via Benzinga
News headline image
Niagen Bioscience to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York
From Niagen Bioscience, Inc
Via Business Wire

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?
Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Niagen Bioscience, Inc. - Common Stock trade on?
Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?
The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market
What is the current price of Niagen Bioscience, Inc. - Common Stock?
The current price of Niagen Bioscience, Inc. - Common Stock is 5.130
When was Niagen Bioscience, Inc. - Common Stock last traded?
The last trade of Niagen Bioscience, Inc. - Common Stock was at 02/05/26 04:00 PM ET
What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?
The market capitalization of Niagen Bioscience, Inc. - Common Stock is 349.85M
How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?
Niagen Bioscience, Inc. - Common Stock has 350M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.